2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. Raf
  5. B-Raf Isoform
  6. B-Raf Control

B-Raf Control

B-Raf Control (1):

Cat. No. Product Name Effect Purity
  • HY-180329
    CG 858-Neg
    		Control
    CG 858-Neg (compound 13) is a negative control for Thalidomide (HY-14658)-derived PROTAC degraders, targeting BRAF and BRAFV600E with Ki values ​​of 9.5 nM and 14.4 nM, respectively. CG 858-Neg inhibits downstream ERK phosphorylation and suppresses BRAFV600E-driven melanoma (e.g., A375 cells, IC50=492 nM) and colorectal cancer (e.g., HT-29 cells, IC50=459 nM) cells. CG 858-Neg can be used in research related to melanoma and colorectal cancer.